[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The neonate has d-transposition of the great arteries (d-TGA) with an intact ventricular septum and a restrictive patent foramen ovale (PFO). This means that oxygenated blood returning from the lungs to the left atrium cannot effectively mix with deoxygenated blood in the right atrium, leading to systemic hypoxemia. Prostaglandin E1 infusion is given to maintain ductal patency, allowing some mixing of blood. However, the cyanosis persists even with supplemental oxygen and a saturated oxygen of 55%, indicating that the restrictive PFO is severely limiting interatrial mixing.\n\nLet's analyze the options:\n\nA. Emergent arterial switch operation: While an arterial switch operation is the definitive surgical repair for d-TGA, it is a complex procedure and may not be the immediate priority when the primary issue is inadequate interatrial mixing. Stabilizing the mixing is crucial before definitive repair.\n\nB. Balloon atrial septostomy: This procedure creates or enlarges an atrial septal defect, facilitating better mixing of oxygenated and deoxygenated blood between the atria. In a neonate with d-TGA and a restrictive PFO causing severe hypoxemia, a balloon atrial septostomy (Rashkind procedure) is a critical step to improve oxygenation by increasing interatrial shunting.\n\nC. Extracorporeal membrane oxygenation (ECMO): ECMO is a life support measure used when other interventions have failed or are insufficient. While it can provide oxygenation, it is not the primary treatment for the underlying anatomical problem of inadequate mixing in d-TGA with a restrictive PFO. It would be considered if the infant were unstable or if other measures failed.\n\nD. Inhaled nitric oxide therapy: Inhaled nitric oxide is used to treat pulmonary hypertension. While it can improve oxygenation in some conditions, it does not address the fundamental issue of poor mixing in d-TGA with a restrictive PFO.\n\nE. Atrial septectomy via median sternotomy: This is a surgical procedure to create an atrial septal defect. While it achieves the same goal as a balloon atrial septostomy, a balloon atrial septostomy is a less invasive and faster procedure that can be performed emergently in the cardiac catheterization lab to immediately improve mixing. Atrial septectomy via median sternotomy would be a more definitive surgical intervention, but balloon atrial septostomy is the most appropriate *next step* to improve oxygenation acutely.\n\nGiven the persistent cyanosis and restrictive PFO, the most immediate and appropriate next step is to improve interatrial mixing. A balloon atrial septostomy is the standard and most effective intervention for this purpose in this scenario.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-002", "question": "A 58-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab presents with 6 weeks of progressive dyspnea and dry cough. HRCT shows diffuse ground-glass opacities with areas of consolidation in a peribronchovascular distribution. Bronchoalveolar lavage reveals 45% lymphocytes with CD4/CD8 ratio of 0.5. Methotrexate pneumonitis is suspected. Which histopathologic pattern is most commonly associated with methotrexate-induced lung toxicity?", "options": ["Usual interstitial pneumonia", "Diffuse alveolar damage", "Hypersensitivity pneumonitis pattern", "Organizing pneumonia", "Pulmonary alveolar proteinosis"], "answer": "C", "answer_index": 2, "explanation": "Methotrexate-induced lung toxicity most commonly manifests as a hypersensitivity pneumonitis pattern, characterized by lymphocytic alveolitis with low CD4/CD8 ratio, granulomas, and interstitial inflammation. The BAL findings of elevated lymphocytes with inverted CD4/CD8 ratio support this diagnosis. While organizing pneumonia and diffuse alveolar damage can occur, hypersensitivity pneumonitis is the predominant pattern. UIP pattern is more characteristic of RA-ILD itself rather than drug toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The question describes a patient with rheumatoid arthritis on methotrexate and adalimumab who presents with progressive dyspnea and cough. HRCT shows diffuse ground-glass opacities and consolidation in a peribronchovascular distribution. Bronchoalveolar lavage shows a lymphocytic predominance with a low CD4/CD8 ratio. Methotrexate pneumonitis is suspected.\n\nWe need to identify the histopathologic pattern most commonly associated with methotrexate-induced lung toxicity.\n\nLet's consider the options:\n\nA. Usual interstitial pneumonia (UIP) is the characteristic pattern of idiopathic pulmonary fibrosis. While it can occur in patients with connective tissue diseases, it's not the most common pattern for drug-induced lung disease like methotrexate pneumonitis.\n\nB. Diffuse alveolar damage (DAD) is a pattern seen in acute lung injury, such as ARDS. While methotrexate can cause DAD, it's often a more acute presentation, and other patterns are more frequently described.\n\nC. Hypersensitivity pneumonitis pattern can be seen with some drug reactions, but it typically involves a more nodular or centrilobular pattern and often has a different cellular infiltrate.\n\nD. Organizing pneumonia (OP), formerly known as bronchiolitis obliterans with organizing pneumonia (BOOP), is a well-recognized and common histopathologic pattern associated with methotrexate-induced lung toxicity. It is characterized by the presence of polypoid plugs of granulation tissue within alveolar spaces and small airways. The clinical presentation and HRCT findings described in the question are also consistent with methotrexate pneumonitis, which can manifest with organizing pneumonia.\n\nE. Pulmonary alveolar proteinosis (PAP) is characterized by the accumulation of surfactant-like material in the alveoli. This is not a typical pattern seen with methotrexate toxicity.\n\nGiven the options and the common associations with methotrexate-induced lung toxicity, organizing pneumonia is the most frequently observed histopathologic pattern.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with severe preeclampsia, a condition characterized by widespread endothelial dysfunction. This dysfunction leads to increased vascular permeability, allowing fluid to leak from the capillaries into the interstitial space, including the lungs, causing pulmonary edema.\n\nLet's analyze the other options:\n\n*   **A. Systolic heart failure from peripartum cardiomyopathy:** While peripartum cardiomyopathy can cause pulmonary edema, the echocardiogram shows a preserved ejection fraction of 65%, which is not consistent with significant systolic heart failure.\n*   **C. Volume overload from iatrogenic fluid administration:** While fluid administration can contribute to pulmonary edema, the central venous pressure (CVP) of 4 mmHg is low, suggesting that volume overload is not the primary driver in this case.\n*   **D. Diastolic dysfunction from acute afterload mismatch:** The patient does have diastolic dysfunction (grade III, elevated E/e' ratio of 18), and preeclampsia itself increases afterload. However, the primary mechanism of pulmonary edema in preeclampsia is more directly attributed to endothelial dysfunction and increased capillary permeability rather than solely an afterload mismatch leading to diastolic failure. While diastolic dysfunction contributes to the difficulty in managing fluid, the initial leak is due to permeability.\n*   **E. Mitral regurgitation from papillary muscle dysfunction:** Papillary muscle dysfunction can lead to mitral regurgitation and pulmonary edema, but there is no specific mention of mitral regurgitation on the echocardiogram, and endothelial dysfunction is a more direct and common cause of pulmonary edema in severe preeclampsia.\n\nTherefore, the most fitting explanation for the pulmonary edema in this context is the increased pulmonary capillary permeability caused by the endothelial dysfunction inherent in severe preeclampsia.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-004", "question": "A 67-year-old man with ischemic cardiomyopathy (EF 25%) and cardiac resynchronization therapy-defibrillator presents after appropriate ICD shock for ventricular tachycardia. He is on maximally tolerated guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Electrophysiology study reveals scar-related reentrant VT from the inferolateral left ventricle. Catheter ablation is performed. Three months later, he has recurrent VT storm despite amiodarone. Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?", "options": ["Mexiletine", "Sotalol", "Ranolazine", "Quinidine", "Dofetilide"], "answer": "A", "answer_index": 0, "explanation": "Mexiletine, a class IB sodium channel blocker, when added to amiodarone in patients with recurrent VT despite amiodarone monotherapy, has shown reduction in VT recurrence and ICD shocks. The MEXICA trial demonstrated this combination's efficacy. Sotalol and dofetilide have proarrhythmic risks in low EF patients. Quinidine has significant toxicity and limited modern data. Ranolazine has some antiarrhythmic properties but lacks robust evidence in scar-related VT. Mexiletine's synergistic sodium channel blockade with amiodarone provides additional substrate modification.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has recurrent ventricular tachycardia storm despite amiodarone, in the setting of ischemic cardiomyopathy with a low ejection fraction and a history of appropriate ICD shocks. He is already on guideline-directed medical therapy. We need to identify an additional pharmacologic therapy with a demonstrated mortality benefit in this specific population.\n\nLet's analyze the options:\n\n*   **A. Mexiletine:** While mexiletine can be used for VT, it has not demonstrated a mortality benefit in this specific population and is generally considered for less severe or refractory cases, often in non-ischemic etiologies.\n*   **B. Sotalol:** Sotalol is a beta-blocker with Class III antiarrhythmic properties. It can be effective for VT, but its mortality benefit in patients with recurrent VT storm and severely reduced EF, especially after other therapies have failed, is not as well-established as other options.\n*   **C. Ranolazine:** Ranolazine is a late sodium channel blocker. It has shown benefit in reducing VT burden and hospitalizations in patients with ICDs and recurrent VT, particularly in the setting of structural heart disease. A substudy of the Ranolazine Implantable Cardioverter-Defibrillator (RVT) trial showed a reduction in VT recurrence and ICD shocks. While not directly a mortality trial, reducing VT burden and shocks in this high-risk population is strongly associated with improved outcomes.\n*   **D. Quinidine:** Quinidine is a Class Ia antiarrhythmic. It has significant proarrhythmic potential and is generally avoided in patients with structural heart disease and reduced EF due to increased mortality risk.\n*   **E. Dofetilide:** Dofetilide is a Class III antiarrhythmic. It is effective for atrial arrhythmias and can be used for ventricular arrhythmias. However, it requires careful inpatient initiation and monitoring due to the risk of torsades de pointes. While it can suppress VT, its specific mortality benefit in this exact scenario of recurrent VT storm refractory to amiodarone and other therapies, in the context of ischemic cardiomyopathy, is not as definitively established as the role of ranolazine in reducing VT burden and shocks.\n\nConsidering the options and the patient's presentation, ranolazine has demonstrated a benefit in reducing VT recurrence and ICD shocks in patients with ICDs and structural heart disease, which indirectly translates to improved outcomes and potentially mortality benefit by preventing life-threatening arrhythmias and shocks. While direct mortality trials for specific antiarrhythmics in this exact refractory VT storm scenario are rare, ranolazine's proven efficacy in reducing VT burden and shocks in similar populations makes it the most appropriate choice among the given options.\n\nThe answer is (C)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with a classic history of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) syndrome. This is an autoinflammatory disorder characterized by recurrent episodes of fever, oral ulcers, pharyngitis, and cervical lymphadenopathy. The episodes typically occur every 4-6 weeks and resolve spontaneously. The laboratory findings of elevated inflammatory markers (CRP, ESR) during episodes are consistent with this diagnosis. Genetic testing for other periodic fever syndromes is negative, which is also typical for PFAPA.\n\nLet's evaluate the treatment options:\n\nA. Colchicine prophylaxis: Colchicine is effective for Familial Mediterranean Fever (FMF) and TRAPS, but not typically the first-line treatment for PFAPA. While some studies have shown benefit, it's not considered to have the highest likelihood of inducing complete remission for PFAPA.\n\nB. Anakinra during episodes: Anakinra is an IL-1 receptor antagonist. IL-1 plays a significant role in the pathogenesis of PFAPA. Anakinra has shown to be highly effective in treating PFAPA, often leading to rapid resolution of symptoms and preventing future episodes when given during an attack. It is considered a very effective treatment for PFAPA.\n\nC. Single-dose corticosteroid at episode onset: Corticosteroids are often used to treat PFAPA and can lead to rapid resolution of symptoms. However, they are typically used for symptomatic relief during an episode and do not prevent future recurrences as effectively as other treatments. Repeated corticosteroid use can also have long-term side effects.\n\nD. Tonsillectomy with or without adenoidectomy: Tonsillectomy is considered the definitive treatment for PFAPA and has a very high success rate in inducing complete remission. Many children with PFAPA experience complete resolution of their symptoms after tonsillectomy. This is often considered the treatment with the highest likelihood of inducing complete remission.\n\nE. Cimetidine prophylaxis: Cimetidine has been investigated for PFAPA, but its efficacy is not as well-established or as high as other treatments.\n\nComparing options B and D, while anakinra is highly effective, tonsillectomy is often considered the definitive treatment with the highest likelihood of *complete and permanent* remission. The question asks for the highest likelihood of inducing *complete remission*. Tonsillectomy is widely recognized as the most effective treatment for achieving this.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-006", "question": "A 45-year-old woman with systemic lupus erythematosus develops acute kidney injury with serum creatinine rising from 1.0 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous RBC casts, and dysmorphic red cells. Complement levels are low. Kidney biopsy reveals diffuse proliferative glomerulonephritis (Class IV-G) with 40% cellular crescents, wire loop lesions, and activity index of 14/24 with chronicity index of 2/12. Anti-dsDNA antibody titer is markedly elevated. Which induction regimen has demonstrated superior renal response rates in this clinical scenario?", "options": ["Mycophenolate mofetil plus glucocorticoids", "Cyclophosphamide (Euro-Lupus protocol) plus glucocorticoids", "Voclosporin plus mycophenolate mofetil plus glucocorticoids", "Rituximab plus mycophenolate mofetil plus glucocorticoids", "Belimumab plus cyclophosphamide plus glucocorticoids"], "answer": "C", "answer_index": 2, "explanation": "The AURORA trial demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and glucocorticoids alone in active lupus nephritis. This triple therapy showed benefit across Class III, IV, and V lupus nephritis. While MMF and cyclophosphamide are established induction agents, the addition of voclosporin (a novel calcineurin inhibitor) provides superior efficacy. Rituximab and belimumab combinations lack the same level of evidence for superior renal response in this setting.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with severe lupus nephritis (Class IV-G) characterized by acute kidney injury, significant proteinuria, active urinary sediment (RBC casts, dysmorphic RBCs), low complement levels, high anti-dsDNA titers, and a high activity index on biopsy with crescents. This indicates severe, active disease requiring aggressive immunosuppression.\n\nLet's analyze the options:\n\n*   **A. Mycophenolate mofetil plus glucocorticoids:** While MMF is a standard treatment for lupus nephritis, it is generally considered less potent than cyclophosphamide for inducing remission in severe proliferative lupus nephritis, especially with crescents.\n\n*   **B. Cyclophosphamide (Euro-Lupus protocol) plus glucocorticoids:** The Euro-Lupus protocol (monthly IV cyclophosphamide for 6 months followed by oral cyclophosphamide or MMF) has been a cornerstone for inducing remission in severe lupus nephritis. It has demonstrated efficacy.\n\n*   **C. Voclosporin plus mycophenolate mofetil plus glucocorticoids:** Voclosporin is a calcineurin inhibitor that, when added to MMF and glucocorticoids, has shown superior renal response rates and reduced the risk of kidney disease progression compared to MMF and glucocorticoids alone in the AURORA 2 study. This combination represents a more recent and potent induction strategy.\n\n*   **D. Rituximab plus mycophenolate mofetil plus glucocorticoids:** Rituximab is a B-cell depleting antibody that has shown efficacy in lupus nephritis, particularly in patients refractory to other treatments or with specific manifestations. However, its superiority as a first-line induction regimen over cyclophosphamide or voclosporin-based regimens in this specific severe scenario is not as definitively established as the other options.\n\n*   **E. Belimumab plus cyclophosphamide plus glucocorticoids:** Belimumab is a B-cell activating factor (BAFF) inhibitor. While it can be used in combination with standard immunosuppression for lupus nephritis, its primary indication is often for patients with active disease despite standard therapy or as maintenance therapy. Combining it with cyclophosphamide and glucocorticoids is a reasonable approach, but the question asks for the regimen with *superior* renal response rates in this specific scenario.\n\nConsidering the options and recent evidence, the combination of voclosporin with MMF and glucocorticoids (Option C) has demonstrated superior renal response rates in clinical trials for severe lupus nephritis compared to MMF alone and has shown comparable or superior efficacy to other induction regimens in achieving renal remission. The AURORA 2 study specifically showed that voclosporin plus MMF and corticosteroids resulted in significantly higher rates of complete renal remission and reduced the risk of kidney disease progression compared to MMF and corticosteroids alone.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-007", "question": "A 72-year-old man is admitted to the ICU with septic shock from pneumonia. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, MAP remains 58 mmHg. Echocardiography shows hyperdynamic left ventricle with EF 75%, small LV cavity, and IVC diameter of 0.8 cm with >50% respiratory variation. Lactate is 6.2 mmol/L. Which vasopressor strategy is most appropriate?", "options": ["Add vasopressin 0.03 units/min", "Add epinephrine infusion", "Add phenylephrine infusion", "Add angiotensin II infusion", "Increase norepinephrine to maximum dose before adding second agent"], "answer": "A", "answer_index": 0, "explanation": "Current sepsis guidelines recommend adding vasopressin (up to 0.03 units/min) as the second-line vasopressor when norepinephrine fails to achieve target MAP, typically when norepinephrine exceeds 0.25-0.5 mcg/kg/min. Vasopressin acts via V1 receptors independent of catecholamine pathways, which may be downregulated in sepsis. The VASST trial showed potential mortality benefit in less severe septic shock. The echocardiographic findings suggest adequate volume status (small IVC with variation indicates fluid responsiveness is exhausted). Angiotensin II is reserved for refractory vasodilatory shock after multiple agents. Phenylephrine may reduce cardiac output.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient is in septic shock refractory to adequate fluid resuscitation and a moderate dose of norepinephrine. The echocardiogram shows a hyperdynamic left ventricle with a small cavity and a collapsible IVC, suggesting adequate preload. The elevated lactate indicates ongoing tissue hypoperfusion.\n\nLet's analyze the options:\n\nA. **Add vasopressin 0.03 units/min:** Vasopressin is a second-line agent in septic shock, particularly when norepinephrine alone is insufficient. It acts on V1 receptors, causing vasoconstriction, and can be synergistic with norepinephrine. The dose provided is a typical starting dose.\n\nB. **Add epinephrine infusion:** Epinephrine has both alpha and beta-adrenergic effects. While it can increase MAP, its beta-1 effects can increase myocardial oxygen demand, which might be detrimental in a critically ill patient. It's often considered when other agents have failed or in specific situations like cardiogenic shock.\n\nC. **Add phenylephrine infusion:** Phenylephrine is a pure alpha-1 agonist. While it increases systemic vascular resistance, it can decrease cardiac output by increasing afterload without a significant increase in contractility. Given the hyperdynamic LV, adding a pure alpha-agonist might not be the most optimal choice for improving perfusion.\n\nD. **Add angiotensin II infusion:** Angiotensin II is a potent vasoconstrictor and is indicated for patients with septic shock who remain hypotensive despite adequate fluid resuscitation and maximal doses of other vasopressors. While it's a valid option, vasopressin is often considered before angiotensin II in many guidelines, especially at this stage.\n\nE. **Increase norepinephrine to maximum dose before adding second agent:** While increasing the norepinephrine dose is an option, the patient is already on a moderate dose (0.5 mcg/kg/min, which is approximately 35 mcg/min for a 70 kg patient). The question asks for the *most appropriate* strategy, and adding a second agent with a different mechanism of action is often preferred over pushing a single agent to its maximum, especially when there are concerns about side effects or limited efficacy. Guidelines often suggest adding a second agent when MAP goals are not met with a single agent at a moderate dose.\n\nConsidering the patient's presentation (septic shock, refractory hypotension, hyperdynamic LV, evidence of hypoperfusion) and the available options, adding vasopressin is a well-established and appropriate next step in management. It complements norepinephrine's action and can help improve MAP and tissue perfusion.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-008", "question": "A 29-year-old primigravida at 34 weeks gestation presents with sudden-onset severe headache and right-sided weakness. Blood pressure is 178/112 mmHg. CT head shows left parietal intracerebral hemorrhage with surrounding edema. MRV demonstrates absence of flow in the superior sagittal sinus and left transverse sinus consistent with cerebral venous thrombosis. Platelet count is 82,000/μL, LDH is elevated, and peripheral smear shows schistocytes. Which is the most appropriate immediate management?", "options": ["Emergent cesarean delivery followed by therapeutic anticoagulation", "Therapeutic anticoagulation with unfractionated heparin", "Platelet transfusion followed by decompressive craniectomy", "Plasma exchange followed by anticoagulation", "Magnesium sulfate and antihypertensives with delayed anticoagulation"], "answer": "A", "answer_index": 0, "explanation": "This patient has cerebral venous thrombosis complicated by hemorrhagic transformation in the setting of HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) evidenced by thrombocytopenia, elevated LDH, and schistocytes. The definitive treatment for HELLP is delivery. While anticoagulation is standard for CVT even with hemorrhage, the underlying HELLP syndrome will not resolve without delivery and may worsen, increasing bleeding risk. Emergent cesarean delivery addresses the root cause, after which therapeutic anticoagulation can be safely initiated. Plasma exchange is for TTP, not HELLP. Delaying anticoagulation without addressing HELLP is inappropriate.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with a complex scenario involving preeclampsia-like symptoms (severe headache, severe hypertension), intracerebral hemorrhage, cerebral venous thrombosis (CVT), and evidence of microangiopathic hemolytic anemia (thrombocytopenia, elevated LDH, schistocytes). This constellation of findings strongly suggests a diagnosis of thrombotic thrombocytopenic purpura (TTP) superimposed on pregnancy, or a severe form of HELLP syndrome with neurological involvement.\n\nLet's analyze the options:\n\nA. Emergent cesarean delivery followed by therapeutic anticoagulation: While delivery might be considered in severe preeclampsia, the primary issue here is likely TTP or a related microangiopathy, not just preeclampsia. Anticoagulation in the acute phase of TTP without addressing the underlying platelet consumption can be dangerous.\n\nB. Therapeutic anticoagulation with unfractionated heparin: Anticoagulation is generally contraindicated in the acute phase of TTP due to the risk of exacerbating bleeding. While CVT is present, the underlying cause of thrombocytopenia and schistocytes needs to be addressed first.\n\nC. Platelet transfusion followed by decompressive craniectomy: Platelet transfusion is generally contraindicated in TTP as it can worsen the microthrombi formation. Decompressive craniectomy might be considered for managing increased intracranial pressure from the hemorrhage, but it doesn't address the underlying cause.\n\nD. Plasma exchange followed by anticoagulation: Plasma exchange is the cornerstone of treatment for TTP. It removes the autoantibodies against ADAMTS13 and replaces deficient ADAMTS13. This is crucial for reversing the microangiopathic process, improving platelet counts, and resolving schistocytes. Once the patient is stabilized and the microangiopathy is controlled, anticoagulation can be considered for the CVT.\n\nE. Magnesium sulfate and antihypertensives with delayed anticoagulation: Magnesium sulfate and antihypertensives are appropriate for managing severe hypertension and preventing eclamptic seizures, which are important in this patient. However, they do not address the underlying TTP or CVT. Delayed anticoagulation without initial treatment for TTP is not optimal.\n\nGiven the evidence of TTP (thrombocytopenia, schistocytes, elevated LDH), plasma exchange is the most critical immediate intervention. Once the microangiopathy is treated, anticoagulation can be safely initiated for the CVT.\n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-009", "question": "A 14-year-old girl presents with 3 months of progressive fatigue, arthralgia, and facial rash. Laboratory evaluation reveals ANA 1:1280 (homogeneous pattern), anti-dsDNA positive, anti-Smith positive, C3 45 mg/dL (normal 90-180), C4 6 mg/dL (normal 10-40), and anti-C1q antibodies positive. Urinalysis shows 2+ protein and 10-15 RBCs/hpf. She is diagnosed with juvenile-onset systemic lupus erythematosus. The presence of anti-C1q antibodies in this patient most specifically predicts which disease manifestation?", "options": ["Neuropsychiatric lupus", "Proliferative lupus nephritis", "Antiphospholipid syndrome", "Lupus pneumonitis", "Autoimmune hemolytic anemia"], "answer": "B", "answer_index": 1, "explanation": "Anti-C1q antibodies have the highest specificity for lupus nephritis, particularly proliferative forms (Class III/IV). Studies demonstrate that anti-C1q antibodies have a negative predictive value approaching 100% for active renal disease-their absence essentially excludes active nephritis. The combination of anti-C1q with anti-dsDNA antibodies and low complement strongly predicts proliferative nephritis. While anti-C1q can be seen in hypocomplementemic urticarial vasculitis, in SLE context, they specifically correlate with renal involvement. Anti-ribosomal P antibodies are more associated with neuropsychiatric lupus.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The question asks about the most specific prediction of anti-C1q antibodies in a patient with juvenile-onset systemic lupus erythematosus (SLE).\n\nLet's analyze the options:\n\n*   **A. Neuropsychiatric lupus:** While neuropsychiatric manifestations can occur in SLE, anti-C1q antibodies are not the most specific predictor for this.\n*   **B. Proliferative lupus nephritis:** Studies have shown a strong association between the presence of anti-C1q antibodies and the development and severity of lupus nephritis, particularly proliferative forms. These antibodies are thought to contribute to immune complex deposition in the glomeruli.\n*   **C. Antiphospholipid syndrome:** Antiphospholipid antibodies (like lupus anticoagulant, anti-cardiolipin, and anti-beta2-glycoprotein I) are the primary predictors of antiphospholipid syndrome. While some overlap can exist, anti-C1q is not the most specific marker for this.\n*   **D. Lupus pneumonitis:** Lupus can affect the lungs, but anti-C1q antibodies are not specifically linked to pneumonitis as a primary predictor.\n*   **E. Autoimmune hemolytic anemia:** Autoimmune hemolytic anemia is a known manifestation of SLE, but anti-C1q antibodies are not the most specific predictor for this condition.\n\nGiven the strong evidence linking anti-C1q antibodies to lupus nephritis, especially proliferative forms, this is the most specific prediction among the choices. The patient's urinalysis findings (proteinuria and hematuria) also support the presence of kidney involvement, making this association even more relevant.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-010", "question": "A 52-year-old man with no prior cardiac history presents with acute anterior STEMI. Primary PCI reveals 100% occlusion of the proximal LAD with TIMI 0 flow. After successful stenting with TIMI 3 flow restoration, he develops cardiogenic shock with blood pressure 78/52 mmHg, heart rate 112 bpm, and cardiac index 1.6 L/min/m². Echocardiography shows akinesis of the anterior wall, apex, and septum with EF 20%. He is started on norepinephrine and dobutamine. Despite escalating support, he remains in refractory shock. Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?", "options": ["Intra-aortic balloon pump", "Impella CP", "TandemHeart", "Veno-arterial ECMO", "Impella 5.5"], "answer": "E", "answer_index": 4, "explanation": "Impella 5.5 provides up to 5.5 L/min of forward flow and the greatest degree of LV unloading among the options by actively aspirating blood from the LV and ejecting it into the ascending aorta. This reduces LV end-diastolic pressure, wall stress, and myocardial oxygen demand while maintaining systemic perfusion. VA-ECMO provides excellent systemic support but increases LV afterload and may worsen pulmonary edema without LV venting. TandemHeart provides good support but requires transseptal puncture. Impella CP provides only 3-4 L/min. IABP provides modest afterload reduction with minimal flow augmentation (0.5 L/min).", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The question asks which mechanical circulatory support device provides the greatest degree of left ventricular unloading in a patient with refractory cardiogenic shock due to an anterior STEMI. Let's analyze the options:\n\nA. Intra-aortic balloon pump (IABP): IABPs provide counterpulsation, augmenting diastolic pressure and reducing afterload. While helpful, their unloading capacity is limited compared to other devices.\n\nB. Impella CP: This is a percutaneous ventricular assist device (VAD) that pumps blood from the left ventricle to the aorta. It can unload the left ventricle by reducing end-diastolic volume and pressure.\n\nC. TandemHeart: This device provides circulatory support by pumping blood from the left atrium to the femoral artery. It unloads the left ventricle by reducing preload.\n\nD. Veno-arterial ECMO (VA-ECMO): VA-ECMO provides both oxygenation and circulatory support by draining venous blood, oxygenating it, and returning it to the arterial circulation. While it can support systemic circulation, its primary mechanism is not direct left ventricular unloading. In fact, if the native left ventricle is still contracting forcefully, VA-ECMO can sometimes worsen left ventricular distension and myocardial strain if not managed carefully.\n\nE. Impella 5.5: This is a higher-flow percutaneous VAD compared to the Impella CP. It is designed to provide more significant left ventricular unloading and support. The Impella 5.5 can achieve higher flow rates and thus a greater degree of unloading than the Impella CP.\n\nConsidering the goal of greatest left ventricular unloading in refractory cardiogenic shock, devices that directly pump blood out of the left ventricle or significantly reduce its workload are preferred. The Impella devices are designed for this purpose. The Impella 5.5 offers a higher flow capacity than the Impella CP, leading to a greater degree of left ventricular unloading. While TandemHeart unloads the LV by reducing preload, and IABP unloads by reducing afterload, the direct pumping action of the Impella 5.5 provides the most substantial reduction in LV end-diastolic volume and pressure, thus achieving the greatest degree of unloading among the given options. VA-ECMO's primary role is systemic support and oxygenation, not direct LV unloading.\n\nThe final answer is $\\boxed{E}$."}]